Market Overview

Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway

Share:
Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway
Related IBB
The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut
The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs
Biotech Stocks Bloodied But Can Now Drive M&A (Seeking Alpha)
Related MYL
The Daily Biotech Pulse: Novartis Positive Liver Drug Trials, Krytstal Prices Offering, LogicBio To Debut
Drug Companies To Disclose Pricing Information In Ads
Hoth Therapeutics Files For $10.5 Million IPO (Seeking Alpha)

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on May 8)

  • CONMED Corporation (NASDAQ: CNMD)
  • Enanta Pharmaceuticals Inc (NASDAQ: ENTA)
  • Helius Medical Technologies Inc (NASDAQ: HSDT)
  • SurModics, Inc. (NASDAQ: SRDX)

Down In The Dumps

(Stocks hitting 52-week lows on May 8)

  • Acasti Pharma Inc (NASDAQ: ACST)
  • Agenus Inc (NASDAQ: AGEN) (has been falling since it reported Q1 results on Monday)
  • Alimera Sciences Inc (NASDAQ: ALIM)
  • Aralez Pharmaceuticals Inc (NASDAQ: ARLZ) (reported Q1 results Tuesday and announced plans to discontinue U.S. commercial business)
  • Celgene Corporation (NASDAQ: CELG)
  • DENTSPLY SIRONA Inc (NASDAQ: XRAY)
  • Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
  • RXi Pharmaceuticals Corp (NASDAQ: RXII)
  • VBI Vaccines Inc (NASDAQ: VBIV)

Medical/Healthcare/Biotech Conferences

  • 2018 Disruptive Growth and Healthcare Conference – May 8-9, in New York City
  • Deutsche Bank 43rd Annual Health Care Conference – May 8-9, at the InterContinental Boston Hotel

See Also: Attention Biotech Investors: Mark Your Calendar For These May PDUFA Action Dates

Stocks In Focus

Opko Posts Better-than-expected results

Opko Health Inc. (NASDAQ: OPK) reported a narrower-than-expected Q1 loss of 8 cents per share on above-consensus revenues of $254.9 million.

The stock rallied 6.21 percent to $3.42 in after-hours trading.

Penumbra's Beat-And-Raise Quarter

Penumbra Inc (NYSE: PEN) swung to a profit in Q1 and reported above-consensus revenues. The company also raised FY18 revenue guidance.

The stock rallied 5.96 percent to $144 after hours.

Synthetic Biologic Posts Narrower-Than-Expected Loss

Synthetic Biologics Inc (NYSE: SYN) reported a loss of 2 cents per share for its Q1, narrower than the loss of 5 cents expected.

The stock jumped 11.28 percent to $0.2773 in after-hours trading.

OpGen Q1 Beats Estimates

OpGen Inc (NASDAQ: OPGN) reported a narrower-than-expected loss and above-consensus revenues for its Q1.

The stock gained 3.68 percent to $1.97 in after-hours trading.

Transenterix Gains On Q1 Beat

Transenterix Inc (NYSE: TRXC) shares were up 12 percent Wednesday morning in reaction to its Q1 results that showed break-even bottom-line results and revenues of $4.8 million. Analysts, on average, estimated a loss of 7 cents per share on revenues of $3.84 million.

On The Radar

The following companies report earnings on Wednesday:

  • Mylan NV (NASDAQ: MYL) Q1 EPS $0.96 Misses $0.98 Estimate, Sales $2.68B Miss $2.75B Estimate
  • Endocyte, Inc. (NASDAQ: ECYT)
  • FibroGen Inc (NASDAQ: FGEN)
  • Jounce Therapeutics Inc (NASDAQ: JNCE) Q1 EPS $(0.40) Misses $(0.31) Estimate, Sales $11.19M Miss $15.64M Estimate
  • Neos Therapeutics Inc (NASDAQ: NEOS) Q1 EPS $(0.50) Misses $(0.48) Estimate, Sales $10.72M Beat $9.79M Estimate
  • AcelRx Pharmaceuticals Inc (NASDAQ: ACRX)
  • Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) Q3 EPS $(0.04) Beats $(0.24) Estimate, Sales $8.19M Miss $9.1M Estimate
  • Arcadia Biosciences Inc (NASDAQ: RKDA)
  • Array Biopharma Inc (NASDAQ: ARRY)
  • Audentes Therapeutics Inc (NASDAQ: BOLD)
  • Collegium Pharmaceutical Inc (NASDAQ: COLL)
  • Glaukos Corp (NYSE: GKOS)
  • Horizon Pharma PLC (NASDAQ: HZNP) Q1 EPS $0.03 Misses $0.07 Estimate, Sales $223.881M Miss $234.17M Estimate
  • Inovio Pharmaceuticals Inc (NASDAQ: INO)
  • Portola Pharmaceuticals Inc (NASDAQ: PTLA)
  • PTC Therapeutics, Inc. (NASDAQ: PTCT)
  • Puma Biotechnology Inc (NASDAQ: PBYI)
  • Viking Therapeutics Inc (NASDAQ: VKTX)
  • Ophthotech Corp (NASDAQ: OPHT) Q1 EPS $(0.36) Beats $(0.40) Estimate
  • Novavax, Inc. (NASDAQ: NVAX)

Posted-In: Biotech Earnings News Guidance FDA Top Stories Pre-Market Outlook Trading Ideas Best of Benzinga

 

Related Articles (ACRX + ACST)

View Comments and Join the Discussion!

These Benzinga Global Fintech Award Finalists Are Pioneering Consumer Engagement

A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street